Berenberg Bank upgraded shares of Hikma Pharmaceuticals (LON:HIK – Free Report) to a buy rating in a report released on Monday morning, Marketbeat.com reports. Berenberg Bank currently has GBX 2,400 ($31.56) price objective on the stock, up from their prior price objective of GBX 2,100 ($27.61).
Several other research analysts have also recently issued reports on HIK. Barclays reaffirmed an equal weight rating and issued a GBX 2,000 ($26.30) price target on shares of Hikma Pharmaceuticals in a report on Tuesday, May 7th. Deutsche Bank Aktiengesellschaft reissued a buy rating and issued a GBX 2,750 ($36.16) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, June 18th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of GBX 2,325 ($30.57).
Check Out Our Latest Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Stock Performance
Hikma Pharmaceuticals Cuts Dividend
The company also recently announced a dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, August 15th will be paid a dividend of $0.32 per share. This represents a yield of 1.37%. The ex-dividend date is Thursday, August 15th. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is currently 9,538.46%.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Stories
- Five stocks we like better than Hikma Pharmaceuticals
- How to Calculate Inflation Rate
- Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio
- How is Compound Interest Calculated?
- Introduction to Fibonacci Retracement Levels
- What Are Dividends? Buy the Best Dividend Stocks
- Top 3 Stocks to Outperform the S&P 500 in a Downturn
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.